-
Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial.
Schmitz JM, Stotts AL, Yoon JH, Northrup TF, Villarreal YR, Yammine L, Weaver MF, Carmody T, Shoptaw S, Trivedi MH. Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial. Journal of Substance Use and Addiction Treatment 2023;151:208987.
-
Integrative data analysis of clinical trials network studies to examine the impact of psychosocial treatments for black people who use cocaine: Study protocol.
Haeny AM, McCuistian C, Burlew AK, Ruglass LM, Espinosa A, Jordan A, Roundtree C, Lopez J, Morgan-Lopez AA. Integrative data analysis of clinical trials network studies to examine the impact of psychosocial treatments for black people who use cocaine: Study protocol. Contemporary Clinical Trials 2023;133:107329.
-
Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder.
Kidd JD, Smiley SL, Coffin PO, Carmody TJ, Levin FR, Nunes EV, Shoptaw SJ, Trivedi MH. Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder. Drug and Alcohol Dependence 2023;250:110899.
-
Supporting practice facilitators in a learning health care system [commentary].
Parchman ML, Ike B, Osterhage K, Johnson A, Baldwin L. Supporting practice facilitators in a learning health care system [commentary]. Permanente Journal 2023:23.035.
-
Psychometrics of the Concise Health Risk Tracking Self-Report (CHRT-SR16) assessment of suicidality in a sample of adults with moderate to severe methamphetamine use disorder: Findings from the ADAPT-2 randomized trial.
Trombello JM, Kulikova A, Nandy K, Carmody T, Bart G, Schmitz J, Kalmin M, Shoptaw S, Trivedi MH. Psychometrics of the Concise Health Risk Tracking Self-Report (CHRT-SR16) assessment of suicidality in a sample of adults with moderate to severe methamphetamine use disorder: Findings from the ADAPT-2 randomized trial. Neuropsychiatric Disease and Treatment 2023; 19:1443-1454.
-
Patient engagement in a multimodal digital phenotyping study of opioid use disorder.
Campbell CI, Chen C, Adams SR, Asyyed A, Athale NR, Does MB, Hassanpour S, Hichborn E, Jackson-Morris M, Jacobson NC, Jones HK, Kotz D, Lambert-Harris CA, Li Z, McLeman B, Mishra V, Stanger C, Subramaniam G, Wu W, Zegers C, Marsch LA. Patient engagement in a multimodal digital phenotyping study of opioid use disorder. Journal of Medical Internet Research 2023;e45556.
-
National Institute on Drug Abuse Clinical Trials Network meeting report: Advancing emergency department initiation of buprenorphine for opioid use disorder.
Cowan E, Perrone J, Bernstein SL, Coupet E, Fiellin DA, Hawk K, Herring A, Huntley K, McCormack R, Venkatesh A, D'Onofrio G. National Institute on Drug Abuse Clinical Trials Network meeting report: Advancing emergency department initiation of buprenorphine for opioid use disorder. Annals of Emergency Medicine 2023;82(3):326-335.
-
Psychometric performance of a substance use symptom checklist to help clinicians assess substance use disorder in primary care.
Matson TE, Hallgren KA, Lapham GT, Oliver M, Wang X, Williams EC, Bradley KA. Psychometric performance of a substance use symptom checklist to help clinicians assess substance use disorder in primary care. JAMA Network Open 2023;6(5):e2316283.
-
Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States.
Lin C, Pham H, Zhu Y, Clingan SE, Lin L, Murphy SM, Campbell CI, Sorrell TR, Liu Y, Mooney LJ, Hser Y. Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. Drug and Alcohol Dependence 2023;242:109711.
-
Exploring the performance of during-treatment substance use outcome measures in predicting longer-term psychosocial functioning and post-treatment abstinence.
Brandt L, Hu M, Nunes EV, Campbell ANC. Exploring the performance of during-treatment substance use outcome measures in predicting longer-term psychosocial functioning and post-treatment abstinence. Drug and Alcohol Dependence 2023;109918.